Evaluation in vitro of the efficacy of colistin methanesulfonate against biofilm-forming multidrug-resistant Pseudomonas aeruginosa (MDRP)

Journal of Infection and Chemotherapy

Volumn 19, Issue 2, 2013, Pages 348-351

  Marumo, Kenji ^a   Komukai, Daisuke ^a   Hirose, Makoto ^a   Nakamura, Hisako ^a   Tanaka, Hironori ^a   Ugajin, Kazuhisa ^b   Nagashima, Goro ^c   Yoshimura, Ashio ^a  

^a SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^b SHOWA UNIVERSITY   (Japan)

^c Toyoko Hospital   (Japan)

Author keywords

Biofilm; Colistin methanesulfonate; Minimum biofilm eradication concentration (MBEC); Multidrug resistant Pseudomonas aeruginosa (MDRP)

Indexed keywords

AMIKACIN; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; IMIPENEM;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATION; CONCENTRATION (PARAMETERS); CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DISK DIFFUSION; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; HUMAN; IN VITRO STUDY; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM ERADICATION BIOFILM CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA; QUALITY CONTROL; REPRODUCIBILITY; SCANNING ELECTRON MICROSCOPY; STRAIN DIFFERENCE;

EID: 84880700129     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-012-0456-x     Document Type: Article

References (19)

1. Schwartz BS, Warren MR, Barkley FA, Landis L. Microbiological and pharmacological studies of colistin sulfate and sodium colistin methanesulfonate. Antibiot Annu 1959-1960;7:41-60.
2. Conway SP, Pond MN, Watson A, Etherington C, Robey HL, Goldman MH. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax. 1997;52:987-93.
3. Endo R, Ishiguro N, Kikuta H. Usefulness of parenteral colistin in treating of lower respiratory infection due to multidrug resistant Pseudomonas aeruginosa. J Jpn Assoc Infect Dis (Kansenshogaku Zasshi). 2005;79:945-50.
4. Montero M, Horcajada JP, Sorli L, Alvarez-Lerma F, Grau S, Riu M, et al. Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection. 2009;37:461-5.
5. Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthew DK, Karageogopoulos DE, et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents. 2010;35:194-9.
6. Durakovic N, Radojcic V, Boban A, Mrsic M, Sertic D, Serventi-Seiwerth D, et al. Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. Intern Med. 2011;50:1009-13.
7. Pamp SJ, Gjermansen M, Johansen HK, Tolker-Nielsen T. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol Microbiol. 2008;68:223-40.
8. Barnett M, Bushby SR, Wilkinson S. Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol. 1964;23:552-74.
9. Beveridge EG, Martin AJ. Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol. 1967;29:125-35.
10. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K. Stability of colistin and colistin methanesulphonate in aqueous media and plasma as determined by high performance liquid chromatography. Antimicrob Agents Chemother. 2003;47:1364-70.
11. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50:1953-8.
12. Olson ME, Ceri H, Morck DW, Buret AG, Read RR. Biofilm bacteria: formation and comparative susceptibility to antibiotics. Can J Vet Res. 2002;66:86-92.
13. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-first informational supplement. M100-S21. CLSI, Wayne; 2011.
14. Hancock RE, Chapple DS. Peptide antibiotics. Antimicrob Agents Chemother. 1999;43:1317-23.
15. Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamics properties of colistin and colistin methanesulfonate for Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 2001;45:781-5.
16. Hogardt M, Schmoldt S, Götzfried M, Adler K, Heesemann J. Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J Antimicrob Chemother. 2004;54:1057-61.
17. Hengzhuang W, Wu H, Ciofu O, Song Z, HØiby N. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob Agents Chemother. 2012;56:2683-90.
18. Mittal R, Sharma S, Chhibber S, Harjai K. Contribution of free radicals to Pseudomonas aeruginosa induced acute pyelonephritis. Microb Pathog. 2008;45:323-30.
19. Kumon H. Pathogenesis and management of bacterial biofilms in the urinary tract. J Infect Chemother. 1996;2:18-28.